Innovative Cardiovascular Solutions

Executive Summary

Innovative Cardiovascular Solutions (ICS) has developed Emblok 360°, a novel whole-body embolic protection device designed to capture and remove emboli during left heart procedures, thereby reducing the risk of procedure-related strokes. The device protects both the brain and the heart, addressing a critical unmet need in structural heart interventions such as transcatheter aortic valve replacement (TAVR) and left atrial appendage occlusion. ICS has received FDA approval for its device, positioning it as a first-in-class solution for comprehensive embolic protection. The company is privately held, based in San Antonio, Texas, and was founded in 2015. With a strong intellectual property portfolio and a clear regulatory pathway, ICS is poised to capture a significant share of the growing embolic protection market, which is expected to expand as more left heart procedures are performed globally. Looking ahead, ICS's key focus is on commercializing Emblok 360° in the United States, building a direct sales force, and establishing partnerships with leading hospitals. The company is also exploring expansion into international markets, particularly Europe, where CE mark approval could open additional revenue streams. Given the FDA approval already secured, ICS is at a critical transition from development to commercial stage. The success of its launch strategy, adoption by interventional cardiologists, and positive clinical outcomes will be pivotal in driving growth. With a compelling value proposition and a scalable business model, ICS presents a promising investment opportunity in the cardiovascular device space.

Upcoming Catalysts (preview)

• Q3 2026Initial US commercial launch and first sales of Emblok 360°80% success
• Q4 2026CE mark approval for European market entry70% success
• TBDPublication of pivotal clinical trial data demonstrating superiority to standard of care60% success